Adicet Bio, Inc.
Adicet Bio
200 Constitution Drive
Menlo Park
California
94025
United States
Website: http://www.adicetbio.com/
About Adicet Bio, Inc.
Adicet Bio, Inc. is a privately held, pre-clinical stage biotechnology company developing novel universal immune cell therapies based on gamma delta T cells engineered with Chimeric Antigen Receptors. Adicet is also focused on identifying and validating cancer specific targets directed to the intracellular proteome and then generating T Cell Receptor-like monoclonal antibodies (TCRLs) directed to these cancer-specific peptide targets presented by MHC Class I complexes. These TCRLs are being used to arm T cells or as T cell engagers in solid tumors. In August 2016, Adicet entered into a strategic collaboration with Regeneron Pharmaceuticals, Inc. to develop next-generation engineered immune-cell therapeutics using Adicet's gamma delta T cell allogeneic platform technology.
For more information, please visit our website at http://www.adicetbio.com.
109 articles with Adicet Bio, Inc.
-
Adicet Reports Fourth Quarter and Full Year 2022 Financial Results and Highlights Recent Company Progress
3/15/2023
Adicet Bio, Inc. (Nasdaq: ACET), a clinical stage biotechnology company discovering and developing allogeneic gamma delta T cell therapies for cancer, today reported financial results and operational highlights for the fourth quarter and year ended December 31, 2022.
-
Adicet Bio to Participate in 2023 Jefferies Biotech on the Bay Summit
3/9/2023
Adicet Bio, Inc. (Nasdaq: ACET), a clinical stage biotechnology company discovering and developing allogeneic gamma delta T cell therapies for cancer, today announced that Chen Schor, President and Chief Executive Officer, and Nick Harvey, Chief Financial Officer, will participate in the 2023 Jefferies Biotech on the Bay Summit being held March 16-17, 2023.
-
Adicet Bio Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4) - February 28, 2023
2/28/2023
REDWOOD CITY, Calif. & BOSTON--( BUSINESS WIRE )-- Adicet Bio, Inc. (Nasdaq: ACET), a clinical stage biotechnology company discovering and developing allogeneic gamma delta T cell therapies for cancer, today announced it granted inducement awards on February 28, 2023.
-
Adicet Bio Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4) - Feb 01, 2023
2/1/2023
Adicet Bio, Inc., a clinical stage biotechnology company discovering and developing allogeneic gamma delta T cell therapies for cancer, announced it granted inducement awards on January 31, 2023.
-
Adicet Bio to Participate in a Fireside Chat at the 2023 Guggenheim Oncology Conference
2/1/2023
Adicet Bio, Inc. today announced that Chen Schor, President and Chief Executive Officer, will participate in a fireside chat at the 2023 Guggenheim Oncology Conference being held from February 8-9, 2023.
-
Adicet Bio Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4) - December 30, 2022
12/30/2022
Adicet Bio, Inc., a clinical stage biotechnology company discovering and developing allogeneic gamma delta T cell therapies for cancer, announced it granted inducement awards on December 30, 2022.
-
Adicet Bio Reports Positive Data from Ongoing ADI-001 Phase 1 Trial in Patients with Relapsed or Refractory Aggressive B-Cell Non-Hodgkin’s Lymphoma (NHL)
12/10/2022
Adicet Bio, Inc., a clinical stage biotechnology company discovering and developing allogeneic gamma delta T cell therapies for cancer, announced positive safety and efficacy data from the Company’s ongoing Phase 1 study of ADI-001 for the potential treatment of relapsed or refractory B-cell NHL.
-
Adicet Bio to Host Investor Webcast to Discuss Updated Clinical Data from Ongoing ADI-001 Phase 1 Trial in Patients with Relapsed or Refractory Aggressive B-Cell Non-Hodgkin’s Lymphoma (NHL)
12/2/2022
Adicet Bio, Inc. today announced that the Company will host a webcast presentation on Sunday, December 11, 2022 at 9:00 a.m. EST to discuss the most recent data-cut from its ongoing Phase 1 study evaluating the safety and tolerability of ADI-001 for the potential treatment of relapsed or refractory B-cell NHL.
-
Adicet Bio Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4) - December 01, 2022
12/1/2022
Adicet Bio, Inc., a clinical stage biotechnology company discovering and developing allogeneic gamma delta T cell therapies for cancer, announced it granted inducement awards on November 30, 2022.
-
Adicet Bio to Present at the Virtual JMP Securities Hematology and Oncology Summit
11/30/2022
Adicet Bio, Inc. (Nasdaq: ACET), a clinical stage biotechnology company discovering and developing allogeneic gamma delta T cell therapies for cancer, today announced that Chen Schor, President and Chief Executive Officer, will present at the virtual JMP Securities Hematology and Oncology Summit being held from December 6-7, 2022.
-
Adicet Bio Appoints Nancy Boman, M.D., Ph.D., as Senior Vice President and Chief Regulatory Officer
11/29/2022
Adicet Bio, Inc. today announced the appointment of Nancy Boman, M.D., Ph.D., as Senior Vice President and Chief Regulatory Officer.
-
Adicet Reports Third Quarter 2022 Financial Results and Provides Business Updates
11/8/2022
Adicet Bio, Inc. (Nasdaq: ACET), a clinical stage biotechnology company discovering and developing allogeneic gamma delta T cell therapies for cancer, today reported financial results and operational highlights for the third quarter ended September 30, 2022.
-
Adicet Bio Showcases Preclinical Data for Four New Pipeline Programs at The Society for Immunotherapy of Cancer (SITC) 37th Annual Meeting
11/7/2022
Adicet Bio Showcases Preclinical Data for Four New Pipeline Programs at The Society for Immunotherapy of Cancer (SITC) 37th Annual Meeting.
-
Adicet Bio Reports ASH Abstract Data from Ongoing ADI-001 Phase 1 Trial in Relapsed or Refractory Aggressive B-Cell Non-Hodgkin’s Lymphoma (NHL)
11/3/2022
Adicet Bio, Inc. (Nasdaq: ACET), a clinical stage biotechnology company discovering and developing allogeneic gamma delta T cell therapies for cancer, today announced that an abstract detailing updated safety and efficacy data from the Company’s Phase 1 study of ADI-001 for the potential treatment of relapsed or refractory B-cell Non-Hodgkin’s lymphoma (NHL) was made available as part of the 64th American Society of Hematology (ASH) Annual Meeting.
-
Adicet Bio to Present at the 2022 Jefferies London Healthcare Conference
11/1/2022
Adicet Bio, Inc. today announced that Chen Schor, President and Chief Executive Officer, will present at the 2022 Jefferies London Healthcare Conference being held from November 15-17, 2022 in London.
-
Adicet Bio Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4) - October 31, 2022
10/31/2022
Adicet Bio, Inc., a clinical stage biotechnology company discovering and developing allogeneic gamma delta T cell therapies for cancer, announced it granted inducement awards on October 31, 2022 under Adicet’s 2022 Inducement Plan as a material inducement to employment to 12 individuals hired by Adicet in October 2022.
-
Adicet Bio to Present Preclinical Data from Allogeneic Gamma Delta T Cell Pipeline Programs at The Society for Immunotherapy of Cancer (SITC) 37th Annual Meeting
10/5/2022
Adicet Bio to Present Preclinical Data from Allogeneic Gamma Delta T Cell Pipeline Programs at The Society for Immunotherapy of Cancer (SITC) 37th Annual Meeting.
-
Adicet Bio Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4) - October 01, 2022
10/1/2022
Adicet Bio, Inc. announced it granted inducement awards on September 30, 2022 under Adicet’s 2022 Inducement Plan as a material inducement to employment to four individuals hired by Adicet in September 2022.
-
Adicet Bio to Present at Upcoming September 2022 Investor Conferences
9/7/2022
Adicet Bio, Inc. announced that company management will participate in two upcoming investor conferences in September.
-
Adicet Bio Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4) - Aug 31, 2022
8/31/2022
Adicet Bio, Inc. announced it granted inducement awards on August 31, 2022 under Adicet’s 2022 Inducement Plan as a material inducement to employment to five individuals hired by Adicet in August 2022.